Skip to main content
SpringerLink
Log in

Amlodipine Compared with Benidipine in the Management of Hypertension: A Systematic Review and Meta-Analysis

  • Review article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Introduction

Benidipine and amlodipine are two well-known drugs used in hypertensive patients with chronic kidney disease (CKD).

Aim

In this systematic review we aimed to compare benidipine and amlodipine in terms of efficacy in the management of hypertensive patients.

Methods

We searched PubMed, Cochrane CENTRAL, SCOPUS and Web of Science for relevant clinical trials and excluded observational studies. Quality appraisal was evaluated according to GRADE and we assessed the risk of bias using the Cochrane’s risk of bias tool. We included the following outcomes: Systolic blood pressure, diastolic blood pressure, heart rate, estimated glomerular filtration rate (eGFR), and urinary albumin/creatinine ratio. Data were pooled as mean differences (MD) with relative 95% confidence intervals (CI).

Results

Eight studies were eligible for our meta-analysis. We found no significant difference between both drugs regarding systolic (MD = − 0.21 [− 1.48, 1.89], (P = 0.81) and diastolic (MD = 0.01[− 0.51, 0.53], (P = 0.97)) blood pressure measurements. The overall heart rate did not differ as well (MD = − 0.03 [− 1.63, 1.57], (P = 0.97)). We found that benidipine was statistically better than amlodipine in terms of eGFR (MD = 1.07 [0.43, 1.71], (P = 0.001)), and urinary albumin/creatinine ratio (MD = − 43.41 [− 53.53, − 33.29], (P < 0.00001)).

Conclusions

Finally we conclude that benidipine seems to show more positive and promising results in the management of hypertensive patients with chronic kidney disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

    Article  CAS  Google Scholar 

  2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.

    Google Scholar 

  3. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28.

    Article  Google Scholar 

  4. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341–52.

    Article  Google Scholar 

  5. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80(1):93–104.

    Article  CAS  Google Scholar 

  6. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.

  7. Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population–the Ohasama study. Nephrol Dial Transplant. 2007;22(7):1910–5.

    Article  Google Scholar 

  8. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69(7):1264–71.

    Article  CAS  Google Scholar 

  9. Takayama T, Yoda S, Yajima Y, Kasamaki Y, Kunimoto S, Kanai T, et al. Improvements in augmentation index and urinary albumin excretion with benidipine in hypertensive patients with chronic kidney disease. Int Heart J. 2016;57(1):53–60.

    Article  CAS  Google Scholar 

  10. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173–81.

    Article  CAS  Google Scholar 

  11. Abe M, Okada K, Suzuki H, Yoshida Y, Soma M. T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease. BMC Nephrol. 2013;14:135.

    Article  CAS  Google Scholar 

  12. Jones SW. Overview of voltage-dependent calcium channels. J Bioenerg Biomembr. 1998;30(4):299–312.

    Article  CAS  Google Scholar 

  13. Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, et al. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res. 2007;30(9):797–806.

    Article  CAS  Google Scholar 

  14. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3–5 chronic kidney disease. Hypertens Res. 2009;32(4):270–5.

    Article  CAS  Google Scholar 

  15. Okuda T, Okamura K, Shirai K, Urata H. Effect of angiotensin-converting enzyme inhibitor/calcium antagonist combination therapy on renal function in hypertensive patients with chronic kidney disease: Chikushi anti-hypertension trial—benidipine and perindopril. J Clin Med Res. 2018;10(2):117–24 (2017/12/30).

  16. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Sugaya T, et al. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. Am J Med Sci. 2010;339(2):157–63.

    Article  Google Scholar 

  17. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). J Chin Integr Med. 2009;7(9):889–96.

  18. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Cochrane Book Series, vol. 674.

  19. Green S, Higgins P, Julian T, Alderson P, Clarke M, Mulrow DC, Oxman DA. Cochrane handbook: cochrane reviews: Ch 8: assessing risk of bias in included studies. In: Cochrane Handbook for: Systematic Reviews of Interventions; 2011. pp. 3–10.

  20. Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, et al. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res. 2011;34(2):268–73.

    Article  CAS  Google Scholar 

  21. Suzuki O, Yoshida T, Tani S, Kato K, Yoneyama A, Hibino T, et al. Antioxidative effects of benidipine hydrochloride in patients with hypertension independent of antihypertensive effects. Arzneimittelforschung. 2011;54(09):505–12.

    Article  Google Scholar 

  22. Miyagawa K, Dohi Y, Nakazawa A, Sugiura T, Yamashita S, Sato K, et al. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. a randomized crossover trial between benidipine and amlodipine. Clin Exp Hypertens. 2010;32(1):1–7.

  23. Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med. 2010;59(3):84–95.

    Article  CAS  Google Scholar 

  24. Wu H-Y, Huang J-W, Lin H-J, Liao W-C, Peng Y-S, Hung K-Y, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008.

    Article  Google Scholar 

  25. Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K, et al. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2008;584(2–3):424–34.

    Article  CAS  Google Scholar 

  26. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.

    Article  CAS  Google Scholar 

  27. Five different profiles of dihydropyridines in blocking T-type Ca (2+) channel subtypes (Ca (v)3.1 (alpha (1G)), Ca (v)3.2 (alpha (1H)), and Ca (v)3.3 (alpha (1I))) expressed in Xenopus oocytes. Abstract—Europe PMC. https://europepmc.org/article/med/19401195(Internet; cited 2020 May 15)

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Fayoum University, Mesalla Aboudy St., Fayoum, 63511, Egypt

    Ahmed Adel Sofy, Ahmed Taha Abdelsattar, Omar Magdy Mohammed & Ahmed Taher Masoud

  2. Department of Internal Medicine, Sebasticook Valley Hospital, Pittsfield, ME, USA

    Mohammad Abrar Shareef

  3. School of Public Health, Jackson State University, Jackson, MS, USA

    Abdulhadi A. Alamodi

  4. Department of Internal Medicine, Icahn School of Medicine, Mt Sinai, Queens, New York, USA

    Nso Nso

  5. Department of Epidemiology and Biostatistics, School of Public Health, Jackson State University, Jackson, USA

    Marinelle Payton

Authors
  1. Ahmed Adel Sofy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed Taha Abdelsattar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omar Magdy Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Abrar Shareef
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abdulhadi A. Alamodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nso Nso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marinelle Payton
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ahmed Taher Masoud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed Taher Masoud.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

No ethical approvals were required for this manuscript.

Funding

No funding was received for this study.

Availability of data

All data of this work are available through contacting the corresponding author.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sofy, A.A., Abdelsattar, A.T., Mohammed, O.M. et al. Amlodipine Compared with Benidipine in the Management of Hypertension: A Systematic Review and Meta-Analysis. High Blood Press Cardiovasc Prev 27, 527–537 (2020). https://doi.org/10.1007/s40292-020-00412-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-020-00412-y

Keywords

Search

Navigation